79:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
GRCh37  with Burrows-Wheeler Alignment  (BWA-MEM) (v0.7.5a) . Indel realign-:@0.147059:0.121273:0.882353:0.121273:0.882353:0.100900:0.147059:0.100900:0.015682:0.013308:0.014746:0.011459:0.010432:0.010432:0.004109:0.003618:0.014723:0.005273:0.006620:0.011459:0.007738:0.012509:0.011413:0.007807:0.007442:0.010866:0.014723:0.007670:0.007533:0.020702:0.011299:0.009108:0.008948:0.005182:0.009039:0.007807:0.007738:0.015066:0.005250:0.005615:0.009861:0.011756:0.017485:0.009039:0.011391:0.006437:0.004109:0.003618:0.006939:0.012098:0.018490:0.013605:0.007533:0.019608:0.012098:0.019608:0.006939:0.007738:0.006939:0.009838:0.010432:0.004497:0.010432:0.004497:0.010432:0.009291:0.006939:0.018214:0.004497:0.007738:0.006894:0.011596:0.011322:0.008948:0.005250:0.007738:0.007442:0.009288:0.009405:0.005250:0.005615:0.009861:0.011737:0.007533
315:@0.733994:0.113657:0.752239:0.113657:0.752239:0.101780:0.733994:0.101780:0.006082:0.006082:0.006082
ment and base recalibration was performed with the Genome Analysis Toolkit (GATK, :@0.147059:0.141852:0.886363:0.141852:0.886363:0.121479:0.147059:0.121479:0.017485:0.009039:0.011391:0.006437:0.004611:0.009085:0.011596:0.011391:0.004611:0.011117:0.009291:0.007873:0.009039:0.004611:0.007442:0.009108:0.009108:0.009405:0.005250:0.005547:0.010820:0.007896:0.008811:0.006437:0.005547:0.010843:0.011756:0.004611:0.014723:0.009291:0.007670:0.004611:0.011505:0.009039:0.007807:0.006024:0.010843:0.007807:0.017488:0.009106:0.011391:0.004611:0.014723:0.005273:0.006620:0.011459:0.004611:0.006620:0.011299:0.009039:0.004611:0.015819:0.009039:0.011596:0.010843:0.017485:0.009039:0.004611:0.014929:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.004611:0.010866:0.011274:0.010934:0.005387:0.010706:0.005273:0.006437:0.004611:0.006939:0.015682:0.013513:0.013354:0.014541:0.004497:0.004109
v3.8.1) . Somatic single nucleotide variants (SNVs) and small insertions and deletions :@0.147059:0.162431:0.886448:0.162431:0.886448:0.142058:0.147059:0.142058:0.009838:0.010432:0.004497:0.010432:0.004497:0.010432:0.006939:0.018243:0.004497:0.004885:0.010592:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004885:0.007604:0.005615:0.011459:0.009927:0.005182:0.009039:0.004885:0.011391:0.011345:0.008765:0.005182:0.009108:0.010820:0.006437:0.005547:0.011322:0.009039:0.004885:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004885:0.006939:0.009770:0.016230:0.015089:0.007670:0.006939:0.004885:0.009085:0.011598:0.011391:0.004885:0.007601:0.017577:0.009405:0.005387:0.005250:0.004885:0.005615:0.011619:0.007875:0.009039:0.007964:0.006437:0.005545:0.010845:0.011619:0.007670:0.004885:0.009085:0.011598:0.011391:0.004885:0.011322:0.008948:0.005182:0.009131:0.006437:0.005547:0.010843:0.011619:0.007670:0.004109
316:@0.204124:0.154815:0.222369:0.154815:0.222369:0.142937:0.204124:0.142937:0.006082:0.006082:0.006082
were called with Strelka (v1.0.14) . The functional effect of the somatic SNVs and indels :@0.147059:0.183009:0.886481:0.183009:0.886481:0.162636:0.147059:0.162636:0.014518:0.009039:0.007442:0.009039:0.003561:0.009108:0.009405:0.005387:0.005182:0.009108:0.011391:0.003561:0.014723:0.005273:0.006617:0.011459:0.003561:0.009793:0.006437:0.007442:0.008948:0.005387:0.010614:0.009291:0.003561:0.006939:0.009838:0.010432:0.004497:0.010432:0.004497:0.010432:0.010432:0.006939:0.018235:0.004497:0.003561:0.011470:0.011311:0.009039:0.003561:0.006369:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.003561:0.009039:0.005969:0.005787:0.009108:0.009108:0.006437:0.003561:0.010843:0.006209:0.003561:0.006620:0.011299:0.009039:0.003561:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.003561:0.009770:0.016230:0.015089:0.007670:0.003561:0.009085:0.011596:0.011391:0.003561:0.005615:0.011596:0.011322:0.008948:0.005250:0.007670:0.004109
317:@0.421333:0.175393:0.439579:0.175393:0.439579:0.163516:0.421333:0.163516:0.006082:0.006082:0.006082
were predicted with SnpEff (v.4.3) . Somatic structural variants (SVs) were called with :@0.147059:0.203588:0.886408:0.203588:0.886408:0.183215:0.147059:0.183215:0.014518:0.009039:0.007442:0.009039:0.004771:0.011071:0.007442:0.009106:0.011391:0.005547:0.009108:0.006209:0.009108:0.011391:0.004771:0.014723:0.005271:0.006620:0.011459:0.004771:0.010112:0.011391:0.011276:0.012098:0.005969:0.005969:0.004771:0.006939:0.008104:0.004497:0.010432:0.004497:0.010432:0.006939:0.018278:0.004497:0.004771:0.010592:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004771:0.007510:0.006437:0.007967:0.011345:0.009108:0.006163:0.011413:0.007898:0.009405:0.005250:0.004771:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004771:0.006939:0.010112:0.015089:0.007670:0.006939:0.004771:0.014518:0.009039:0.007442:0.009039:0.004771:0.009108:0.009405:0.005387:0.005182:0.009108:0.011391:0.004771:0.014723:0.005273:0.006620:0.011459:0.004109
260:@0.433313:0.195972:0.451558:0.195972:0.451558:0.184095:0.433313:0.184095:0.006082:0.006082:0.006082
GRIDSS (v1.8.0) . To assess the SNV overlap between an organoid and a corresponding :@0.147059:0.224167:0.886560:0.224167:0.886560:0.203794:0.147059:0.203794:0.015682:0.013376:0.007259:0.016139:0.010112:0.010112:0.003356:0.006939:0.009838:0.010432:0.004497:0.010432:0.004497:0.010432:0.006939:0.018234:0.004497:0.003356:0.010866:0.011048:0.003356:0.009291:0.007533:0.007875:0.009039:0.007533:0.007670:0.003356:0.006620:0.011299:0.009039:0.003356:0.009770:0.016230:0.015089:0.003356:0.010866:0.009633:0.009039:0.007601:0.005433:0.008811:0.011276:0.003356:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.003356:0.009085:0.011756:0.003356:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.003356:0.009085:0.011598:0.011391:0.003356:0.009291:0.003356:0.008994:0.010845:0.007807:0.007444:0.009039:0.007510:0.011502:0.010845:0.011596:0.011391:0.005615:0.011461:0.009861:0.004109
318:@0.287090:0.216551:0.305335:0.216551:0.305335:0.204673:0.287090:0.204673:0.006082:0.006082:0.006082
tumor sample, SNVs that were only detected in either the tumor or the organoid sample :@0.147059:0.244745:0.886446:0.244745:0.886446:0.224373:0.147059:0.224373:0.006163:0.011413:0.017485:0.010843:0.007807:0.004086:0.007944:0.009085:0.017280:0.011162:0.005182:0.008743:0.004497:0.004086:0.009770:0.016230:0.015089:0.007670:0.004086:0.006620:0.011391:0.008811:0.006437:0.004086:0.014518:0.009039:0.007442:0.009039:0.004086:0.010843:0.011870:0.005182:0.009724:0.004086:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009108:0.011391:0.004086:0.005615:0.011756:0.004086:0.009039:0.005273:0.006620:0.011299:0.009039:0.007807:0.004086:0.006620:0.011299:0.009039:0.004086:0.006166:0.011413:0.017485:0.010843:0.007807:0.004086:0.010845:0.007807:0.004086:0.006620:0.011299:0.009039:0.004086:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004086:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.004109
of a pair were in a subsequent step called in the corresponding sample (tumor or organ-:@0.147059:0.265324:0.882353:0.265324:0.882353:0.244951:0.147059:0.244951:0.010843:0.006209:0.004337:0.009291:0.004337:0.011368:0.009085:0.005615:0.007807:0.004337:0.014518:0.009039:0.007442:0.009039:0.004337:0.005615:0.011756:0.004337:0.009291:0.004337:0.007510:0.011345:0.010934:0.007875:0.009108:0.010706:0.011345:0.009039:0.011391:0.006437:0.004337:0.007510:0.006209:0.009131:0.011276:0.004337:0.009108:0.009405:0.005387:0.005182:0.009106:0.011391:0.004337:0.005615:0.011756:0.004337:0.006620:0.011299:0.009039:0.004337:0.008994:0.010843:0.007807:0.007442:0.009039:0.007510:0.011502:0.010843:0.011598:0.011391:0.005615:0.011459:0.009861:0.004337:0.007944:0.009087:0.017280:0.011160:0.005184:0.009039:0.004337:0.006939:0.006166:0.011413:0.017485:0.010843:0.007807:0.004337:0.010843:0.007807:0.004337:0.010843:0.007624:0.009861:0.009085:0.011751:0.007533
oid) when supported by at least one read.:@0.147059:0.285903:0.490711:0.285903:0.490711:0.265530:0.147059:0.265530:0.010843:0.005547:0.011391:0.006939:0.004109:0.014789:0.011302:0.009039:0.011756:0.004109:0.007510:0.011071:0.011048:0.011502:0.010843:0.007967:0.006209:0.009108:0.011391:0.004109:0.010843:0.009724:0.004109:0.008811:0.006437:0.004109:0.005182:0.009291:0.009291:0.007510:0.006437:0.004109:0.010843:0.011596:0.009039:0.004109:0.007442:0.009291:0.009291:0.011114:0.004497
Copy number alterations (CNAs) were called with PURPLE (v2.17) . PURPLE also as-:@0.147059:0.327060:0.882353:0.327060:0.882353:0.306687:0.147059:0.306687:0.014997:0.010820:0.011094:0.009724:0.003995:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.003995:0.009405:0.004908:0.006209:0.009039:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003995:0.006939:0.014678:0.015406:0.014586:0.007670:0.006939:0.003995:0.014518:0.009039:0.007442:0.009039:0.003995:0.009108:0.009405:0.005387:0.005182:0.009106:0.011391:0.003995:0.014723:0.005273:0.006620:0.011459:0.003995:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.003995:0.006939:0.009838:0.010432:0.004497:0.010432:0.010432:0.006939:0.018176:0.004497:0.003995:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.003995:0.009405:0.005250:0.007875:0.011048:0.003995:0.009291:0.007643:0.007533
284:@0.712633:0.319444:0.730879:0.319444:0.730879:0.307567:0.712633:0.307567:0.006082:0.006082:0.006082
sesses tumor purity. In case of low tumor purity, a “NO_TUMOR” quality flag was raised :@0.147059:0.347639:0.886411:0.347639:0.886411:0.327266:0.147059:0.327266:0.007875:0.009039:0.007533:0.007875:0.009039:0.007670:0.003812:0.006163:0.011413:0.017485:0.010843:0.007807:0.003812:0.011048:0.011413:0.007807:0.005273:0.006437:0.007989:0.004497:0.003812:0.006894:0.011756:0.003812:0.009106:0.009291:0.007875:0.009039:0.003812:0.010843:0.006209:0.003812:0.005182:0.010866:0.014723:0.003812:0.006163:0.011413:0.017485:0.010843:0.007807:0.003812:0.011048:0.011413:0.007807:0.005273:0.006437:0.007989:0.004497:0.003812:0.009291:0.003812:0.006848:0.015887:0.016412:0.011413:0.013354:0.015499:0.019197:0.016047:0.011550:0.007647:0.003812:0.010706:0.011596:0.009402:0.005250:0.005273:0.006437:0.009724:0.003812:0.005638:0.005821:0.009197:0.009861:0.003812:0.014723:0.009291:0.007670:0.003812:0.007898:0.009085:0.005615:0.007875:0.009108:0.011391:0.004109
by PURPLE, meaning PURPLE failed to find any aneuploidy, and somatic variants were :@0.147059:0.368218:0.886459:0.368218:0.886459:0.347845:0.147059:0.347845:0.010843:0.009724:0.004212:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.004497:0.004209:0.017485:0.009291:0.009085:0.011756:0.005615:0.011459:0.009861:0.004212:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.004212:0.006209:0.009085:0.005752:0.005182:0.009108:0.011391:0.004209:0.006211:0.011048:0.004209:0.005684:0.005684:0.011596:0.011391:0.004212:0.009085:0.011368:0.009724:0.004212:0.009085:0.011596:0.009131:0.011071:0.011162:0.005182:0.010845:0.005545:0.011324:0.007987:0.004497:0.004212:0.009087:0.011596:0.011391:0.004212:0.007873:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004212:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004212:0.014518:0.009039:0.007442:0.009039:0.004109
supplied but there were fewer than 300 with observed VAF > 0.1, indicating a high nor-:@0.147059:0.388796:0.882353:0.388796:0.882353:0.368423:0.147059:0.368423:0.007510:0.011071:0.011048:0.011162:0.005250:0.005547:0.009108:0.011391:0.004565:0.010797:0.011071:0.006437:0.004565:0.006620:0.011299:0.009039:0.007442:0.009039:0.004565:0.014518:0.009039:0.007442:0.009039:0.004565:0.006026:0.009336:0.014518:0.009039:0.007807:0.004565:0.006620:0.011391:0.009085:0.011756:0.004565:0.010432:0.010432:0.010432:0.004565:0.014723:0.005271:0.006620:0.011459:0.004565:0.010957:0.010934:0.007875:0.009039:0.008400:0.009633:0.009108:0.011391:0.004565:0.012578:0.014929:0.011276:0.004565:0.011550:0.004565:0.010432:0.004497:0.010432:0.004497:0.004565:0.005615:0.011598:0.011391:0.005547:0.009108:0.008811:0.006437:0.005615:0.011459:0.009861:0.004565:0.009291:0.004565:0.011459:0.005615:0.009930:0.011459:0.004565:0.011596:0.010843:0.007302:0.007533
mal cell content (:@0.147059:0.409375:0.291438:0.409375:0.291438:0.389002:0.147059:0.389002:0.017577:0.009405:0.005250:0.004109:0.008994:0.008948:0.005387:0.005250:0.004109:0.008994:0.010843:0.011391:0.006209:0.009039:0.011391:0.006437:0.004109:0.006939
Table S7:@0.291462:0.409375:0.365009:0.409375:0.365009:0.388242:0.291462:0.388242:0.011413:0.009679:0.011528:0.005935:0.009473:0.004018:0.010592:0.010911
). For tumor samples MC-3.2, MC-3.3, MBT-2.1 and MC-1.2, :@0.365016:0.409375:0.886403:0.409375:0.886403:0.389002:0.365016:0.389002:0.006939:0.004497:0.004109:0.010683:0.010843:0.007807:0.004109:0.006163:0.011413:0.017485:0.010843:0.007807:0.004109:0.007944:0.009087:0.017280:0.011160:0.005182:0.009039:0.007670:0.004109:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.004497:0.004109:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.004497:0.004109:0.019608:0.012395:0.011801:0.007533:0.010432:0.004497:0.010432:0.004109:0.009085:0.011596:0.011391:0.004109:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.004497:0.004109
based on manual verification, a wrong ploidy level was automatically selected by PUR-:@0.147059:0.429954:0.882353:0.429954:0.882353:0.409581:0.147059:0.409581:0.011117:0.009291:0.007875:0.009108:0.011391:0.005182:0.010843:0.011756:0.005182:0.017577:0.009085:0.011391:0.011596:0.009405:0.005250:0.005182:0.009635:0.009039:0.007807:0.005615:0.005684:0.005613:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.005182:0.009291:0.005182:0.014723:0.007442:0.010843:0.011459:0.009861:0.005182:0.011162:0.005182:0.010843:0.005547:0.011322:0.009724:0.005182:0.005182:0.009334:0.009635:0.008948:0.005250:0.005182:0.014723:0.009291:0.007670:0.005182:0.008811:0.011071:0.006209:0.010843:0.017577:0.008811:0.006437:0.005547:0.009108:0.009402:0.005387:0.005182:0.009724:0.005182:0.007875:0.008948:0.005182:0.009108:0.009108:0.006209:0.009108:0.011391:0.005182:0.010843:0.009724:0.005182:0.012167:0.016024:0.012281:0.007533
PLE. We verified with metaphase spreads analysis on MC-3.2, MBT-2.1 and MC-1.2 :@0.147059:0.450532:0.886553:0.450532:0.886553:0.430160:0.147059:0.430160:0.011664:0.011619:0.012098:0.004497:0.006917:0.018649:0.009039:0.006917:0.009633:0.009039:0.007807:0.005615:0.005684:0.005615:0.009106:0.011391:0.006917:0.014723:0.005273:0.006620:0.011459:0.006917:0.017485:0.009131:0.006551:0.008811:0.011162:0.011391:0.009291:0.007875:0.009039:0.006917:0.007512:0.011069:0.007444:0.009288:0.009291:0.011391:0.007670:0.006917:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.006917:0.010843:0.011756:0.006917:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.004497:0.006917:0.019608:0.012395:0.011801:0.007533:0.010432:0.004497:0.010432:0.006917:0.009085:0.011596:0.011391:0.006917:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.004109
PDOs that a ploidy of 2 was most likely for those PDOs and tumor samples. Therefore, :@0.147059:0.471111:0.886471:0.471111:0.886471:0.450738:0.147059:0.450738:0.011664:0.016504:0.016253:0.007670:0.004942:0.006620:0.011391:0.008811:0.006437:0.004942:0.009291:0.004953:0.011162:0.005182:0.010843:0.005547:0.011322:0.009724:0.004942:0.010843:0.006209:0.004942:0.010432:0.004942:0.014723:0.009291:0.007670:0.004942:0.017488:0.010955:0.007512:0.006437:0.004942:0.005250:0.005752:0.010272:0.008948:0.005182:0.009724:0.004942:0.006026:0.010843:0.007807:0.004942:0.006620:0.011299:0.010957:0.007875:0.009039:0.004942:0.011664:0.016504:0.016253:0.007670:0.004942:0.009085:0.011598:0.011391:0.004942:0.006163:0.011413:0.017485:0.010843:0.007807:0.004942:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.004942:0.011470:0.011311:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008745:0.004497:0.004109
and due to the impossibility of manually correcting the ploidy selection in PURPLE, we :@0.147059:0.491690:0.886446:0.491690:0.886446:0.471317:0.147059:0.471317:0.009085:0.011596:0.011391:0.004406:0.011048:0.011345:0.009039:0.004406:0.006209:0.011048:0.004406:0.006620:0.011299:0.009039:0.004406:0.005615:0.017280:0.011505:0.010957:0.007533:0.007601:0.005547:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.004406:0.010845:0.006209:0.004406:0.017577:0.009087:0.011391:0.011596:0.009402:0.005387:0.005182:0.009724:0.004406:0.008994:0.010843:0.007807:0.007442:0.009108:0.009108:0.006437:0.005615:0.011459:0.009861:0.004406:0.006620:0.011299:0.009039:0.004406:0.011162:0.005184:0.010840:0.005549:0.011322:0.009724:0.004406:0.007875:0.008948:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004406:0.005615:0.011756:0.004406:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.004497:0.004406:0.014518:0.009039:0.004109
ran Control-FREEC (v. 11.0)  instead on all samples (tumor and PDO) from those pa-:@0.147059:0.512269:0.882353:0.512269:0.882353:0.491896:0.147059:0.491896:0.007898:0.009085:0.011756:0.004314:0.014997:0.010843:0.011391:0.006437:0.007442:0.010934:0.005250:0.007533:0.011276:0.013376:0.012098:0.012098:0.014678:0.004314:0.006939:0.008104:0.004497:0.004314:0.010432:0.010432:0.004497:0.010432:0.006939:0.018268:0.004314:0.005615:0.011619:0.007510:0.006209:0.009291:0.009291:0.011391:0.004314:0.010843:0.011756:0.004314:0.009405:0.005387:0.005250:0.004314:0.007941:0.009087:0.017280:0.011162:0.005182:0.009039:0.007670:0.004314:0.006939:0.006163:0.011413:0.017485:0.010843:0.007807:0.004314:0.009085:0.011596:0.011391:0.004314:0.011664:0.016504:0.016412:0.006939:0.004314:0.006414:0.007442:0.010843:0.017645:0.004314:0.006620:0.011299:0.010957:0.007873:0.009039:0.004314:0.011368:0.009376:0.007533
319:@0.389388:0.504653:0.407633:0.504653:0.407633:0.492775:0.389388:0.492775:0.006082:0.006082:0.006082
tients. Telomeric and centromeric regions were masked for visualization.:@0.147059:0.532847:0.754226:0.532847:0.754226:0.512474:0.147059:0.512474:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.004109:0.010866:0.008948:0.005182:0.010843:0.017485:0.009039:0.007807:0.005547:0.008994:0.004109:0.009085:0.011596:0.011391:0.004109:0.008994:0.009039:0.011391:0.006437:0.007442:0.010843:0.017485:0.009039:0.007807:0.005547:0.008994:0.004109:0.007442:0.009039:0.009861:0.005547:0.010843:0.011619:0.007670:0.004109:0.014518:0.009039:0.007442:0.009039:0.004109:0.017577:0.009291:0.007556:0.010272:0.009108:0.011391:0.004109:0.006024:0.010843:0.007807:0.004109:0.009838:0.005615:0.007510:0.011596:0.009405:0.005250:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497
For samples CCC-1, END-1.1, END-1.2, HGS-22 and HGS-23 no normal reference :@0.147059:0.574005:0.886395:0.574005:0.886395:0.553632:0.147059:0.553632:0.010683:0.010843:0.007807:0.007213:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.007213:0.014744:0.014746:0.014678:0.007533:0.010432:0.004497:0.007213:0.012098:0.016230:0.016139:0.007533:0.010432:0.004497:0.010432:0.004497:0.007213:0.012098:0.016230:0.016139:0.007533:0.010432:0.004497:0.010432:0.004497:0.007213:0.016412:0.015682:0.010112:0.007533:0.010432:0.010432:0.007213:0.009085:0.011598:0.011391:0.007213:0.016412:0.015682:0.010112:0.007533:0.010432:0.010432:0.007213:0.011596:0.011048:0.007213:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.007213:0.007442:0.009039:0.006026:0.009039:0.007442:0.009039:0.011596:0.008994:0.009039:0.004109
sample was available for somatic mutation calling. In these cases, germline SNV calling :@0.147059:0.594583:0.886551:0.594583:0.886551:0.574210:0.147059:0.574210:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.004862:0.014723:0.009291:0.007670:0.004862:0.008925:0.009838:0.009087:0.005750:0.005433:0.009108:0.010911:0.005182:0.009039:0.004862:0.006026:0.010843:0.007807:0.004862:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004862:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.004862:0.009108:0.009405:0.005387:0.005250:0.005615:0.011459:0.009676:0.004497:0.004862:0.006894:0.011756:0.004862:0.006620:0.011299:0.009039:0.007875:0.009039:0.004862:0.009108:0.009291:0.007875:0.009039:0.007670:0.004497:0.004862:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.004862:0.009770:0.016230:0.015089:0.004862:0.009108:0.009402:0.005387:0.005250:0.005615:0.011459:0.009861:0.004109
was performed with GATK  and only SNVs with a “HIGH” or “MODERATE” effect :@0.147059:0.615162:0.886531:0.615162:0.886531:0.594789:0.147059:0.594789:0.014723:0.009291:0.007670:0.005844:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.005844:0.014723:0.005273:0.006620:0.011459:0.005844:0.015682:0.013513:0.013354:0.014541:0.018218:0.005844:0.009085:0.011596:0.011391:0.005844:0.010843:0.011870:0.005182:0.009724:0.005844:0.009770:0.016230:0.015089:0.007670:0.005844:0.014723:0.005273:0.006620:0.011459:0.005844:0.009291:0.005844:0.006848:0.016846:0.006825:0.015682:0.016205:0.007647:0.005844:0.010843:0.007807:0.005844:0.006391:0.019197:0.016047:0.015773:0.012098:0.013650:0.013513:0.013354:0.011528:0.007647:0.005844:0.009039:0.005969:0.005784:0.009108:0.009108:0.006437:0.004109
316:@0.382422:0.607546:0.400668:0.607546:0.400668:0.595669:0.382422:0.595669:0.006082:0.006082:0.006082
as predicted by SnpEff were considered. Similarly, germline SV calling was performed :@0.147059:0.635741:0.886487:0.635741:0.886487:0.615368:0.147059:0.615368:0.009291:0.007670:0.005889:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006209:0.009108:0.011391:0.005889:0.010843:0.009724:0.005889:0.010112:0.011391:0.011276:0.012098:0.005969:0.005969:0.005889:0.014518:0.009039:0.007442:0.009039:0.005889:0.008994:0.010843:0.011619:0.007601:0.005547:0.011322:0.009039:0.007442:0.009108:0.011117:0.004497:0.005889:0.010112:0.005615:0.017645:0.005752:0.005433:0.009085:0.007601:0.005182:0.007989:0.004497:0.005889:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.005889:0.010112:0.015089:0.005889:0.009108:0.009405:0.005387:0.005250:0.005615:0.011459:0.009861:0.005889:0.014723:0.009291:0.007670:0.005889:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.004109
using GRIDSS and SV calls were filtered against the SV Panel of Normals from the HMF :@0.147059:0.656319:0.886462:0.656319:0.886462:0.635947:0.147059:0.635947:0.011413:0.007601:0.005615:0.011459:0.009861:0.003801:0.015682:0.013376:0.007259:0.016139:0.010112:0.010112:0.003798:0.009085:0.011596:0.011391:0.003801:0.010112:0.015089:0.003798:0.009108:0.009405:0.005387:0.005250:0.007670:0.003801:0.014518:0.009039:0.007442:0.009039:0.003798:0.005684:0.005821:0.004908:0.006209:0.009039:0.007442:0.009108:0.011391:0.003801:0.009199:0.009861:0.009085:0.005615:0.011619:0.007510:0.006437:0.003798:0.006620:0.011302:0.009039:0.003798:0.010112:0.015089:0.003801:0.011413:0.009085:0.011596:0.008948:0.005250:0.003801:0.010843:0.006209:0.003798:0.015522:0.010843:0.007807:0.017579:0.009402:0.005250:0.007670:0.003801:0.006414:0.007442:0.010843:0.017645:0.003798:0.006622:0.011299:0.009039:0.003798:0.016846:0.019608:0.011276:0.004109
analysis pipeline, which can be found in https://resources.hartwigmedicalfoundation.nl. :@0.147059:0.676898:0.886462:0.676898:0.886462:0.656525:0.147059:0.656525:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.003958:0.011071:0.005273:0.011505:0.008948:0.005250:0.005615:0.011596:0.008743:0.004497:0.003960:0.014789:0.011459:0.005547:0.008765:0.011459:0.003960:0.009108:0.009085:0.011756:0.003958:0.011254:0.009039:0.003958:0.006026:0.010820:0.011413:0.011598:0.011391:0.003958:0.005615:0.011756:0.003959:0.011094:0.006163:0.006163:0.011185:0.007670:0.004497:0.007099:0.007099:0.007442:0.009039:0.007875:0.010820:0.011413:0.007442:0.008994:0.009039:0.007670:0.004497:0.011391:0.009085:0.007967:0.006437:0.014723:0.005615:0.009861:0.017485:0.009108:0.011391:0.005547:0.009108:0.009405:0.005250:0.006026:0.010820:0.011413:0.011596:0.011573:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.011868:0.004975:0.004497:0.004109
 :@0.480161:0.676898:0.484270:0.676898:0.484270:0.656525:0.480161:0.656525:0.004109
Since PURPLE requires tumor-normal pairs, CNA calling for these five samples was per-:@0.147059:0.697477:0.882353:0.697477:0.882353:0.677104:0.147059:0.677104:0.010112:0.005615:0.011596:0.008994:0.009039:0.003470:0.012167:0.016024:0.013376:0.011664:0.011619:0.012098:0.003470:0.007442:0.009108:0.010706:0.011413:0.005615:0.007442:0.009039:0.007670:0.003470:0.006163:0.011413:0.017485:0.010843:0.007236:0.007533:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.003470:0.011365:0.009087:0.005615:0.007622:0.007670:0.004497:0.003470:0.014678:0.015408:0.014929:0.003470:0.009108:0.009405:0.005387:0.005250:0.005615:0.011459:0.009861:0.003470:0.006024:0.010845:0.007807:0.003470:0.006620:0.011299:0.009039:0.007875:0.009039:0.003470:0.005684:0.005615:0.009635:0.009039:0.003470:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.003470:0.014723:0.009291:0.007670:0.003470:0.011505:0.009039:0.007165:0.007533
formed individually with Control-FREEC (v. 11.0) .:@0.147059:0.718056:0.593574:0.718056:0.593574:0.697683:0.147059:0.697683:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.004109:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011046:0.011596:0.009405:0.005387:0.005182:0.009724:0.004109:0.014723:0.005273:0.006620:0.011459:0.004109:0.014997:0.010843:0.011391:0.006437:0.007442:0.010934:0.005250:0.007533:0.011276:0.013376:0.012098:0.012098:0.014678:0.004109:0.006939:0.008101:0.004497:0.004109:0.010432:0.010432:0.004497:0.010432:0.006939:0.018243:0.004497
319:@0.570832:0.710440:0.589077:0.710440:0.589077:0.698562:0.570832:0.698562:0.006082:0.006082:0.006082
 :@0.147059:0.759213:0.151167:0.759213:0.151167:0.738840:0.147059:0.738840:0.004109
Assessment of homologous recombination status:@0.147059:0.777850:0.589985:0.777850:0.589985:0.754690:0.147059:0.754690:0.010409:0.010409:0.010409:0.009214:0.010409:0.010409:0.014817:0.009363:0.011679:0.008367:0.003984:0.011256:0.008840:0.003984:0.011579:0.011256:0.014817:0.011256:0.008691:0.011256:0.011206:0.011256:0.011156:0.010409:0.003984:0.011231:0.009363:0.011007:0.011256:0.014817:0.010982:0.004856:0.011679:0.009458:0.008616:0.004856:0.011256:0.011679:0.003984:0.010309:0.007520:0.009463:0.008616:0.011156:0.010409
To identify homologous recombination (HR)-deficient samples, :@0.147059:0.803604:0.686953:0.803604:0.686953:0.783231:0.147059:0.783231:0.010866:0.011048:0.004018:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006503:0.009724:0.004018:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.004018:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004018:0.006939:0.016846:0.013376:0.006939:0.007533:0.011320:0.009039:0.005684:0.005615:0.008994:0.005547:0.009039:0.011391:0.006437:0.004018:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.004109
BRCA1:@0.686834:0.804073:0.754059:0.804073:0.754059:0.782051:0.686834:0.782051:0.013217:0.013468:0.014495:0.015157:0.010888
 and :@0.754059:0.803604:0.794257:0.803604:0.794257:0.783231:0.754059:0.783231:0.004018:0.009085:0.011596:0.011391:0.004109
BRCA2:@0.794156:0.804073:0.861380:0.804073:0.861380:0.782051:0.794156:0.782051:0.013217:0.013468:0.014495:0.015157:0.010888
 as :@0.861380:0.803604:0.886466:0.803604:0.886466:0.783231:0.861380:0.783231:0.004018:0.009291:0.007670:0.004109
well as other genes in the HR-pathway (:@0.147059:0.824183:0.493170:0.824183:0.493170:0.803810:0.147059:0.803810:0.014518:0.008948:0.005387:0.005250:0.006175:0.009291:0.007670:0.006175:0.010820:0.006620:0.011299:0.009039:0.007807:0.006175:0.009656:0.009039:0.011596:0.009039:0.007670:0.006175:0.005615:0.011756:0.006175:0.006620:0.011299:0.009039:0.006175:0.016846:0.012349:0.007533:0.011368:0.008811:0.006620:0.011071:0.014723:0.008925:0.009724:0.006175:0.006939
BARD1, BRIP1, CHEK2, FANCA, PALB2, :@0.493170:0.824652:0.887572:0.824652:0.887572:0.802630:0.493170:0.802630:0.012806:0.015157:0.013673:0.016161:0.010888:0.005364:0.007852:0.013217:0.013673:0.007647:0.012646:0.010888:0.005364:0.007852:0.014495:0.016937:0.012760:0.014906:0.010888:0.005364:0.007852:0.010797:0.015157:0.016002:0.014495:0.015157:0.005364:0.007852:0.011185:0.015157:0.012144:0.013217:0.010888:0.005364:0.005227
RAD50, RAD51(B/C/D):@0.147059:0.845231:0.368593:0.845231:0.368593:0.823208:0.147059:0.823208:0.014038:0.015157:0.016161:0.010888:0.010888:0.005364:0.008012:0.014038:0.015157:0.016161:0.010888:0.010888:0.007715:0.013217:0.007350:0.014495:0.007350:0.016161:0.007601
) were assessed for biallelic inactivation, incorporating both :@0.368596:0.844762:0.886442:0.844762:0.886442:0.824389:0.368596:0.824389:0.006939:0.006300:0.014518:0.009039:0.007442:0.009039:0.006300:0.009291:0.007533:0.007875:0.009039:0.007531:0.007875:0.009108:0.011391:0.006300:0.006026:0.010843:0.007807:0.006300:0.010820:0.005798:0.009405:0.005387:0.005182:0.008948:0.005250:0.005547:0.008994:0.006300:0.005615:0.011687:0.009291:0.009108:0.006437:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.006300:0.005615:0.011596:0.008994:0.010843:0.007967:0.011505:0.010843:0.007898:0.008811:0.006437:0.005615:0.011459:0.009861:0.006300:0.011254:0.010820:0.006620:0.011459:0.004109
germline and somatic WGS data. Biallelic inactivation was defined as: a deep deletion :@0.147059:0.865340:0.886434:0.865340:0.886434:0.844967:0.147059:0.844967:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.005866:0.009085:0.011596:0.011391:0.005866:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005866:0.020270:0.015682:0.010112:0.005866:0.011571:0.008811:0.006551:0.009291:0.004497:0.005866:0.012486:0.005798:0.009405:0.005387:0.005182:0.008948:0.005250:0.005547:0.008994:0.005866:0.005615:0.011687:0.009291:0.009106:0.006437:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.005866:0.014723:0.009291:0.007670:0.005866:0.011322:0.009039:0.005684:0.005684:0.011596:0.009108:0.011391:0.005866:0.009291:0.007670:0.004497:0.005866:0.009291:0.005866:0.011322:0.009108:0.009128:0.011276:0.005866:0.011322:0.008948:0.005182:0.009131:0.006437:0.005547:0.010843:0.011756:0.004109
(i.e. full loss of both alleles); or Loss-Of-Heterozygosity (LOH) in combination with (i) :@0.147059:0.885919:0.886532:0.885919:0.886532:0.865546:0.147059:0.865546:0.006939:0.005341:0.004497:0.008743:0.004497:0.005227:0.006369:0.011550:0.005387:0.005250:0.005227:0.005182:0.010957:0.007533:0.007670:0.005227:0.010845:0.006209:0.005227:0.011254:0.010820:0.006620:0.011459:0.005227:0.009405:0.005387:0.005182:0.008946:0.005184:0.009039:0.007670:0.006939:0.004497:0.005227:0.010843:0.007807:0.005227:0.011824:0.010957:0.007531:0.007670:0.007533:0.016298:0.006209:0.007533:0.016207:0.009131:0.006209:0.009039:0.007442:0.010934:0.008834:0.009633:0.009656:0.010957:0.007601:0.005273:0.006437:0.009724:0.005227:0.006939:0.011525:0.016047:0.016846:0.006939:0.005227:0.005615:0.011756:0.005227:0.008994:0.010843:0.017396:0.010820:0.005615:0.011687:0.008811:0.006437:0.005545:0.010845:0.011756:0.005227:0.014723:0.005273:0.006620:0.011459:0.005227:0.006939:0.005615:0.006939:0.004109
a known pathogenic/likely pathogenic variant according to ClinVar (https://www.ncbi.:@0.147059:0.906498:0.882352:0.906498:0.882352:0.886125:0.147059:0.886125:0.009291:0.005136:0.010706:0.011596:0.010866:0.014723:0.011756:0.005136:0.011368:0.008811:0.006620:0.011299:0.011048:0.009656:0.009039:0.011756:0.005547:0.008994:0.007099:0.005250:0.005752:0.010272:0.008948:0.005182:0.009724:0.005136:0.011368:0.008811:0.006620:0.011299:0.011048:0.009656:0.009039:0.011756:0.005547:0.008994:0.005136:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.005136:0.009291:0.008994:0.008994:0.010843:0.007442:0.011391:0.005615:0.011459:0.009861:0.005136:0.006209:0.011048:0.005136:0.014746:0.005250:0.005615:0.011756:0.012874:0.009085:0.007807:0.005136:0.006939:0.011094:0.006163:0.006163:0.011185:0.007670:0.004497:0.007099:0.007099:0.015271:0.015269:0.012988:0.004497:0.011596:0.008857:0.010820:0.005341:0.004497